Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Resource Type
Article
Authors
Luo, Suxia ; Peng, Feng ; Wu, Gang ; Xu, Nong ; Zhao, Lin ; Ma, Dong ; Qin, Shukui ; Ren, Wei ; Li, Enxiao ; Lu, Hongda ; Pan, Yueyin ; Xiong, Jianping ; Yuan, Ying ; Bai, Yuxian ; Chen, Lei ; Hu, Yi ; Zhang, Li ; Gao, Yong ; Huang, Jing ; Xu, Jianming ; Chen, Yun ; Zhuang, Wu ; Zhang, Yiping ; Chen, Zhendong ; Chen, Jia ; Zhang, Helong ; Niu, Zuoxing ; Fan, Qingxia ; Lin, Lizhu ; Gu, Kangsheng ; Liu, Ying ; Ba, Yi ; Miao, Zhanhui ; Jiang, Xiaodong ; Zeng, Ming ; Chen, Jianhua ; Fu, Zhichao ; Gan, Lu ; Wang, Jun ; Zhan, Xianbao ; Liu, Tianshu ; Li, Zhiping ; Shen, Lin ; Shu, Yongqian ; Zhang, Tao ; Yang, Qing ; Zou, Jianjun
Source
In The Lancet Oncology June 2020 21(6):832-842
Subject
Primary Research Articles
Language
ISSN
1470-2045